NPC1 Inactivation Reduces SARS-CoV-2 Entry by Decreasing ACE2 Levels
Author Information
Author(s): La Rosa Piergiorgio, Tiberi Jessica, Palermo Enrico, Stefanelli Roberta, Tiano Sofia Maria Luigia, Canterini Sonia, Cortese Mirko, Hiscott John
Primary Institution: Sapienza University of Rome
Hypothesis
NPC1 inactivation generates an unfavorable barrier to SARS-CoV-2 entry by affecting ACE2 localization.
Conclusion
Inhibiting NPC1 activity significantly reduces SARS-CoV-2 entry into host cells by depleting ACE2 from the plasma membrane.
Supporting Evidence
- Inhibition of NPC1 with U18666A significantly reduced SARS-CoV-2 infectivity.
- ACE2 levels decreased at the plasma membrane in NPC1-inhibited cells.
- CRISPR/Cas9-edited cells showed resistance to SARS-CoV-2 infection.
- U18666A treatment led to a >40-fold reduction in virus titer.
- NPC1 inactivation altered cholesterol distribution in cells.
Takeaway
When a protein called NPC1 is blocked, it helps stop the virus that causes COVID-19 from getting into cells by lowering the amount of a helper protein called ACE2 on the cell surface.
Methodology
The study used pharmacological inhibition and CRISPR/Cas9 gene editing to assess the effects of NPC1 on SARS-CoV-2 entry in various cell lines.
Limitations
The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website